Peroxisome proliferator-activated receptors (PPARs) are key mediators of energy homeostasis, and lipid and glucose metabolism that exhibit circadian expression. PPAR activating drugs are used clinically as lipid and glucose-lowering drugs. We evaluated the effect of long-term (11 weeks) PPARa and PPARg activation using bezafibrate and rosiglitazone, respectively, on metabolism, locomotor activity and feeding rhythms of non-obese mice. We found that bezafibrate, but not rosiglitazone, led to no weight gain and a slight weight loss with reduced epididymal fat pads. Although rosiglitazone had a minor effect on 24-h food intake rhythm, bezafibrate treatment was accompanied by increased amplitude and an advanced acrophase of the 24-h feeding rhythm. Similarly, unlike rosiglitazone, bezafibrate treatment was accompanied by a significantly advanced acrophase of locomotor activity rhythm under constant darkness conditions. As disrupted circadian rhythms lead to obesity, PPARa activation can serve as a clinical target for the modulation of both circadian rhythms and metabolism.
INTRODUCTION
Mammalian homeostatic systems have adapted to daily changes in light and dark by developing an endogenous circadian clock located in the suprachiasmatic nuclei of the anterior hypothalamus. 1 The core circadian clock is encoded by the genes Clock, brain --muscle-Arnt-like 1 (Bmal1), Period1 (Per1), Period2 (Per2), Cryptochrome1 (Cry1), and Cryptochrome2 (Cry2). The proteins CLOCK and BMAL1 dimerize to activate transcription of a large number of genes, including those of the negative feedback loop, Pers and Crys. When PER and CRY proteins are produced in the cytoplasm, they oligomerize and translocate to the nucleus to inhibit CLOCK:BMAL1-mediated transcription. 1 The circadian clock regulates metabolism and energy homeostasis by mediating the expression and/or activity of certain enzymes and transport systems involved in metabolism. 2 As a result, disrupted circadian rhythms lead to attenuated circadian feeding rhythms, hyperphagia, diabetes and obesity 3 reiterating the strict control of the circadian clock over metabolism. Peroxisome proliferator-activated receptors (PPARs) are key mediators of energy homeostasis, and lipid and glucose metabolism. 4 These key metabolic factors have been shown to be tightly linked to the core clock mechanism. 2 PPARs bind directly to the Bmal1 promoter and, in turn, the CLOCK:BMAL1 heterodimer regulates PPAR expression. 5, 6 PPARa and PPARg possess significant clinical value, as PPAR isoform-specific agonists, specifically fibrates for PPARa and thiazolidinedione for PPARg, are currently prescribed as lipid and glucose-lowering drugs, respectively. 4 PPAR-activating drugs have been reported to affect circadian rhythms. The PPARa agonist fenofibrate reset rhythmic expression and increased transcription of clock genes in the liver. 6 Another PPARa agonist, bezafibrate, was shown to stimulate Per2 phase advance in peripheral tissues. 7, 8 In addition, locomotor activity of mice with delayed sleep phase syndrome can be restored by bezafibrate administration. 7 Similarly, the PPARa agonist, rosiglitazone, induced Bmal1 expression. 9 Hence, the interdependence of circadian and metabolic systems jointly regulated by PPARs appears to be extremely important. Herein, our objective was to test the effect of PPARa and PPARg activation using bezafibrate and rosiglitazone, respectively, on metabolism, locomotor activity and feeding circadian rhythms of healthy, non-obese and young mice.
MATERIALS AND METHODS

Animals, treatments and tissues
Twelve-week-old male C57BL/6J mice (n ¼ 18) (Harlan Laboratories, Jerusalem, Israel) were singly housed in a temperature-and humiditycontrolled facility (23 --24 1C, 60% humidity) and entrained to a light --dark cycle (12 h light (500 lux) and 12 h darkness, LD), with regular chow (Harlan Laboratories) and water available ad libitum. After acclimation, mice were treated for 11 weeks with 80 mg/kg/day bezafibrate or 10 mg/kg/day rosiglitazone (Cayman Chemical Company, Ann Arbor, MI, USA) in the diet, as was previously described. 8 A control group was fed regular chow. On the last day, mice were fasted for 12 h and killed by cervical dislocation following anesthesia. Terminal blood glucose levels were determined using Optium Xceed glucometer (Abbott Laboratories Ltd, Maidenhead, UK) and epididymal fat pads and liver were harvested. Fat pads were weighed whereas the liver was immediately frozen in liquid nitrogen and stored in À80 1C for further analysis. Liver total lipids were extracted and measured, as was described. 10 The experiment was conducted in full compliance with the strict guidelines of the Hebrew University policy on animal care and use.
Locomotor activity measurement and analysis General cage activity was monitored using a custom-made system composed of infrared detectors placed above each cage, as was previously described.
11 Double-plotted actograms were generated using the Actogram software. Period length of circadian activity rhythm during 11 days in DD (tau) was calculated individually by Chi-square analyses using the Tau software. Acrophase in DD conditions was calculated by the Acro software using individual circadian activity period length. Actogram (version 3.5), Tau (version 6.5) and Acro (version 3.5) softwares were kindly provided by Refinetti R., University of South Carolina (Walterboro, SC, USA).
Western blot analysis
Liver tissue samples (200 mg) were homogenized in 1 ml of lysis buffer (20 mM Tris, 145 mM NaCl, 10% glycerol, 5 mM EDTA, 1% Triton-X, 0.5% Nonidet P-40, 100 mM PMSF, 50 mmol/l NaF and 1 mM sodium orthovanadate). Samples were run onto an SDS-polyacrylamide gel (10%) and after electrophoresis proteins were transferred onto nitrocellulose membranes. Blots were incubated with AMP-activated protein kinase (AMPK) or phosphoAMPK (pAMPK) (Cell Signaling Technology, Danvers, MA, USA) and Actin (MP Biomedicals, Solon, OH, USA) antibodies and after several washes with horseradish peroxidase-labeled secondary antibody (Pierce, Rockford, IL, USA). The immune reaction was detected by enhanced chemiluminescence. Finally, bands were quantified by scanning and densitometry and expressed as arbitrary units.
Statistical analysis
All results are expressed as means ± S.E. Significance of feeding and activity rhythms were evaluated by ANOVA with repeated measures (STATISTICA 7.0, StatSoft, Inc., Tulsa, OK, USA) and by Cosinor Periodogram software (Acrophase software University of South Carolina, Walterboro, SC, USA, Version 3.5). The effect of the different drugs and number of days under treatment, on body weight, total 24 h food intake and 24 h food intake rhythm were analyzed by repeated measures ANOVA followed by post-hoc analysis; or by student's t-test (paired or unpaired), when appropriate. For the effect on biochemical profile a one-way ANOVA followed by post-hoc analysis test was performed for comparisons between groups. For all analyses, the significance level was set at Po0.05.
RESULTS
We set out to test the effect of PPARa and PPARg activation using bezafibrate and rosiglitazone, respectively, on metabolism, locomotor activity and feeding circadian rhythms. As obesity affects circadian rhythms, 12 we tested the effect of these drugs on nonobese mice.
Effect of bezafibrate and rosiglitazone on body weight Eleven weeks of rosiglitazone treatment of normal weight mice led to the same weight gain seen in the control group (Figure 1a) . In contrast, bezafibrate treatment prevented the weight gain observed in the control group. Since Day 45, bezafibrate-treated mice had a significantly lower body weight than the control group (ANOVA, Po0.05) (Figure 1a) . Bezafibrate treatment even led to a moderate, nearly significant, weight loss vs baseline (26.6 ± 1.2 g vs. 24.9±1.2 g; t-test, P ¼ 0.07) (Figure 1a) . Total 24-h food intake was similar among the three groups throughout the experiment (Figure 1b) .
Effect of bezafibrate and rosiglitazone on metabolic parameters As expected from healthy, normal weight mice, all three groups showed similar fasting glucose levels (data not shown). Liver lipid content also did not differ among the groups (Figure 1c) . However, epididymal fat pads were significantly lower both in bezafibrate-and rosiglitazone-treated groups compared with control mice (Figure 1d ). We then evaluated the effect of the drugs on AMPK in the liver, as AMPK is a key-regulator of energy homeostasis. The ratio between activated AMPK and total AMPK levels (pAMPK/AMPK) did not differ among the groups (Figure 1e ).
Effect of bezafibrate and rosiglitazone on feeding rhythms Rosiglitazone had a minor effect on 24-h food intake rhythm after 58 days of treatment and affected only the amplitude (control, 0.33; rosiglitazone, 0.46; ratio, 1.4) (Figure 1f) . In contrast, bezafibrate treatment was accompanied by increased amplitude and a 30-min advanced acrophase of the 24-h feeding rhythm after 58 days of treatment (amplitude: control, 0.33; bezafibrate, 0.42; ratio, 1.27; acrophase: control, ZT18.20; bezafibrate, ZT17.70) (Figure 1f ).
Effect of bezafibrate and rosiglitazone on locomotor activity Locomotor activity under LD conditions was not affected by both drugs and all groups exhibited similar 24-h activity rhythms peaking during the dark phase (Figure 2a) . We next tested the effect of the drugs on circadian locomotor rhythm in constant darkness (DD), preventing the masking and entraining effect of light (Figure 2b) . Under DD conditions, mice exhibited a period slightly shorter than 24 h that was not different among the groups (Figure 2c ). Unlike rosiglitazone, bezafibrate treatment was accompanied by a significantly advanced acrophase vs control of the circadian activity rhythm under DD conditions (control, CT17.32 ± 0.54 h; bezafibrate, CT15.17 ± 0.68 h, t-test, Po0.05) (Figure 2d ). These results support the advance seen in the acrophase of the feeding rhythm (Figure 1f) . White and black bars at the top of each actogram represent the light and dark periods. Period length of circadian activity rhythm in DD (tau) was calculated individually by Chi-square analyses using Tau software. Acrophase in DD conditions was calculated by Acro software using individual period length. Values are means±s.e., n ¼ 6 for each group. *Po0.05.
DISCUSSION
Using lean, young mice, we showed the effect of bezafibrate on circadian rhythms, without obesity being a confounder. Our results show that bezafibrate, unlike rosiglitazone, advances feeding and locomotor activity circadian rhythms. Though lean mice were used in this study, we could still see weight loss in bezafibrate-treated mice although total 24-h food intake was similar to other groups. This similarity in food intake alongside weight loss in the bezafibrate-treated mice suggests elevated energy expenditure. The reduction in epididymal fat mass in both bezafibrate-and rosiglitazone-treated groups could explain the lower body weight of the bezafibrate-treated animals and a different fat distribution that led to no change in body weight of the rosiglitazone-treated mice. In the liver, the level of activated AMPK did not differ among the groups, suggesting no change in the inhibition of acetyl CoA carboxylase, an AMPK substrate and the rate-limiting enzyme in fatty acid synthesis. These results suggest that fatty acid synthesis was not blocked as a result of bezafibrate treatment, supporting the finding of similar lipid levels in the liver (Figure 1c) . Altogether, these results support the notion that the reduction in body weight in the bezafibrate-treated mice stems from increased fatty acid oxidation, the result of PPARa activation, rather than reduced fatty acid synthesis.
Bezafibrate led to increased amplitude and advanced feeding rhythms, suggesting that bezafibrate can be used to modulate circadian rhythms. Under LD, we could not detect any advanced locomotor activity. These results are in contrast with recently published data 7, 8 showing a phase advance of 3 h under LD conditions. These differences can stem from differences in the light intensities and spectral composition of the lights or the strains used in the studies (Jcl:ICR vs C57BL) leading to differences in the masking effect of light. Another possibility is the longer duration (11 weeks) of drug administration in this study. However, our results under DD are similar to those previously published, 7 showing an advance in locomotor activity. The higher amplitude and advanced circadian phase as a result of bezafibrate treatment can be explained by the fact that PPARa is a positive regulator of Bmal1 expression. 6 Activation of PPARa leads to increased levels of BMAL1 protein, which may lead to elevated functions of clock output systems, such as feeding and locomotor activity rhythms. Although PPARg was also found to be a positive regulator of Bmal1, 9 we detected only increased amplitude in the feeding rhythms with no phase advance in the rosiglitazone-treated animals. These results may suggest that PPARa is a stronger regulator of Bmal1 expression than PPARg. As high amplitude circadian rhythms lead to reduced inflammation and improved health, 11 bezafibrate treatment may lead not only to reduced body weight, but also to reduced inflammation, as indeed has recently been shown. 13 However, as our results were obtained in healthy animals, further studies should determine the effect of bezafibrate on circadian rhythms in obese or diabetic animals. As PPARa and the biological clock are mutually regulated and disrupted circadian rhythms lead to obesity, PPARa activation can serve as a clinical target for the modulation of both circadian rhythms and metabolism. However, it needs to be determined whether the effect on phase of entrainment is dependent on the light intensity during the LD condition. If higher light levels 'overrule' the phasing effect of bezafibrate, PPARa may not be an attractive target for drug treatment of obesity. Nonetheless, similar studies need to be performed in human subjects to support our findings.
